ASPIRE BIOPHARMA HOLDINGS, INC. — Net Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c5b360c5-1a61-4dff-b3ef-f87b7b082069/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-24.5M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-013682 |
| FY 2024 | $-1.3M | 2024-01-01 – 2024-12-31 | evidence 0001493152-26-013682 |
| FY 2023 | $4.5M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-009602 |
| FY 2022 | $3.3M | 2022-01-01 – 2022-12-31 | evidence 0001410578-23-000316 |
| FY 2021 | $-25.5k | 2021-02-09 – 2021-12-31 | evidence 0001410578-23-000316 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).